Why Express, Roku and Insys Therapeutics slumped Today – The Motley Fool

The stock market has gone much higher lately, and Wednesday was no exception. A 0.6% gain for the Dow Jones Industrial Average matched well with equally large jumps in other major indices, with investors taking comfort from encouraging macro-economic readings. Nevertheless, although much of the market continued to build on gains from earlier in the week, some stocks could not participate in the rally. Express (NYSE: EXPR) Roku (NASDAQ: ROKU) and Insys Therapeutics (NASDAQ: INSY) among the worst artists. That's why they made it so bad.

Express looks a bit shabby

Expresses' shares dropped 1

0% after the clothing retailer launched the fourth quarter financial results. Express said revenue fell 10% year-on-year, mainly due to a 6% decline in comparable sales over the period. Part of the decline stems from the fact that it was a minor week in the period, but the need for more generous campaigns to move goods damaged the company's margins. Express also expects further deterioration in the coming quarter, including a comparable sales stoppage of 9% to 11%. With the dealer choosing not to give all year 2019 guidance given uncertain trends and the absence of a permanent CEO, Express shareholders seem even more nervous than they did in December if the company has gone out of fashion for good.

Is Roku flying too high?

Roku's share fell 14% after smart TV expert got some negative comments from stock analysts. Macquarie downgraded the shares from superior to neutral, while Loop Capital continued, took it from wait to sell. After huge gains so far in 2019, the Roku shares have already reflected much of the upside potential of the company's business, and some fear that copy providers will eventually be able to challenge the early success Roku has had. If moving from relying solely on hardware to getting customers to the streaming service, Rokus upside can remain completely intact.

Insys deal with great doubt

Finally, the shares of Insys Therapeutics went 25%. The opioid-based treatment manufacturer said an auditor has expressed negative views on whether Insys can continue to function as an ongoing business, which is essentially accounting language to stay in business. With allegations that the company's executives paid bribes to increase prescription volumes for its Cancer Pain Treatment Subsys, they could be about $ 100 million in cash on Insys & # 39; balance being insufficient to handle rising attorney fees, settlements, and other costs. Until these issues are resolved, Insys will have trouble building trust among its shareholders.

Dan Caplinger has no position in any of the aforementioned shares. Motley Fool has no position in any of the aforementioned shares. Motley Fool has a disclosure policy.